What is the optimal BCG dose in non-muscle-invasive bladder cancer?
Witjes
J Alfred
JA
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000627:therapeutic use; D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009361:Neoplasm Invasiveness; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine